Zymeworks: H.C. Wainwright Welcomes the Strategic Realignment - Analysts Raise Price Target and See Now 85% Potential
Reading Time: 2 minutes
Zymeworks (ZYME) took a significant step towards long-term financial security in early March 2026 by completing a $250 million royalty-backed financing deal with Royalty Pharma. From the company's perspective, this move is essential to secure the ongoing stock buyback program, potential strategic acquisitions, and overall liquidity beyond 2028 without shareholder-dilutive capital measures. The repayment of these funds will occur through the assignment of 30% of the global tiered royalties from the drug Ziihera, while Zymeworks retains the remaining...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
